Skip to main content Skip to navigation
BB700 Mouse Anti-Rat CD54
Product Details
Down Arrow Up Arrow


BD OptiBuild™
ICAM-1; Icam1; ICAM; Intercellular adhesion molecule 1
Rat (Tested in Development)
Mouse BALB/c IgG1, κ
Rat HEV-Derived Cell Line Ax
Flow cytometry (Qualified)
0.2 mg/ml
AB_2743239
Aqueous buffered solution containing ≤0.09% sodium azide.
RUO


Preparation And Storage

Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze. The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography. The antibody was conjugated with BD Horizon BB700 under optimal conditions that minimize unconjugated dye and antibody.

Recommended Assay Procedures

For optimal and reproducible results, BD Horizon Brilliant Stain Buffer should be used anytime two or more BD Horizon Brilliant dyes are used in the same experiment. Fluorescent dye interactions may cause staining artifacts which may affect data interpretation. The BD Horizon Brilliant Stain Buffer was designed to minimize these interactions. More information can be found in the Technical Data Sheet of the BD Horizon Brilliant Stain Buffer (Cat. No. 563794 or 566349).

When setting up compensation, it is recommended to compare spillover values obtained from cells and BD™ CompBeads to ensure that beads will provide sufficiently accurate spillover values.

For optimal results, it is recommended to perform two washes after staining with antibodies. Cells may be prepared, stained with antibodies and washed twice with wash buffer per established protocols for immunofluorescent staining prior to acquisition on a flow cytometer. Performing fewer than the recommended wash steps may lead to increased spread of the negative population.

Product Notices

  1. This antibody was developed for use in flow cytometry.
  2. The production process underwent stringent testing and validation to assure that it generates a high-quality conjugate with consistent performance and specific binding activity. However, verification testing has not been performed on all conjugate lots.
  3. Researchers should determine the optimal concentration of this reagent for their individual applications.
  4. An isotype control should be used at the same concentration as the antibody of interest.
  5. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
  6. For fluorochrome spectra and suitable instrument settings, please refer to our Multicolor Flow Cytometry web page at www.bdbiosciences.com/colors.
  7. Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
  8. BD Horizon Brilliant Stain Buffer is covered by one or more of the following US patents: 8,110,673; 8,158,444; 8,575,303; 8,354,239.
  9. BD Horizon Brilliant Blue 700 is covered by one or more of the following US patents: 8,455,613 and 8,575,303.
  10. Cy is a trademark of GE Healthcare.
745779 Rev. 1
Antibody Details
Down Arrow Up Arrow
1A29

The 1A29 monoclonal antibody specifically recognizes ICAM-1 which is also known as CD54. ICAM-1 is an 85 kDa type I transmembrane glycoprotein that is encoded by Icam1 (Intercellular adhesion molecule 1). It is expressed on vascular endothelium in lymphoid tissues, thymic stromal cells, peripheral blood monocytes, peritoneal macrophages and mast cells, dendritic cells, and weakly on peripheral lymphocytes and thymocytes. ICAM-1 is a ligand for LFA-1 (CD11a/CD18) and Mac-1 (CD11b/CD18). Its expression is upregulated on activated lymphocytes and endothelial cells. 1A29 mAb inhibits Phorbol 12-Myristate 13-Acetate (PMA)-induced aggregation of phytohemagglutinin (PHA)-stimulated splenic blasts, as well as the adhesion of mitogen-stimulated blasts to high endothelial venule (HEV) cells and purified ICAM-1. The 1A29 antibody can reportedly inhibit leucocyte infiltration in in vivo systems, blocks induction of experimental allergic encephalomyelitis, and reduces NK-cell adhesion to tumor cells.

The antibody was conjugated to BD Horizon™ BB700, which is part of the BD Horizon Brilliant™ Blue family of dyes.   It is a polymer-based tandem dye developed exclusively by BD Biosciences.  With an excitation max of 485 nm and an emission max of 693 nm, BD Horizon BB700 can be excited by the 488 nm laser and detected in a standard PerCP-Cy™5.5 set (eg, 695/40-nm filter). This dye provides a much brighter alternative to PerCP-Cy5.5 with less cross laser excitation off the 405 nm and 355 nm lasers.

745779 Rev. 1
Format Details
Down Arrow Up Arrow
BB700
The BD Horizon Brilliant™ Blue 700 (BB700) Dye is part of the BD Horizon Brilliant™ Blue family of dyes. This tandem fluorochrome is comprised of a polymer-technology dye donor with an excitation maximum (Ex Max) of 476-nm and an acceptor dye with an emission maximum (Em Max) at 695-nm. Driven by BD innovation, BB700 is designed to be excited by the blue laser (488-nm) and detected using an optical filter centered near 695-nm (e.g., a 695/20-nm bandpass filter). The donor dye can be excited by the Violet (405 nm) laser and the acceptor dye can be excited by the red (627–640 nm) laser resulting in cross-laser excitation and fluorescence spillover. BB700 Reagents are significantly brighter than equivalent PerCP or PerCP-Cy5.5 reagents and are less sensitive to photobleaching. In addition, BB700 shows much less excitation by the violet (407-nm) laser resulting in less spillover. BB700 has minimal yellow green (562-nm) excitation and is ideal for instruments with both blue (488-nm) and yellow green (562-nm) lasers. Please ensure that your instrument’s configurations (lasers and optical filters) are appropriate for this dye.
altImg
BB700
Blue 488 nm
476 nm
695 nm
745779 Rev.1
Citations & References
Down Arrow Up Arrow

Development References (16)

  1. Andrews FJ, Malcontenti-Wilson C, O'Brien PE. Expression of adhesion molecules and leukocyte recruitment into gastric mucosa following ischemia-reperfusion. Dig Dis Sci. 1997; 42(2):326-332. (Biology). View Reference
  2. Bañuls MP, Alvarez A, Ferrero I, Zapata A, Ardavin C. Cell-surface marker analysis of rat thymic dendritic cells. Immunology. 1993; 79(2):298-304. (Clone-specific). View Reference
  3. Chen-Woan M, Delaney CP, Fournier V, et al. In vitro characterization of rat bone marrow-derived dendritic cells and their precursors. J Leukoc Biol. 1996; 59(2):196-207. (Clone-specific). View Reference
  4. Divya Jyothi M, Varalakshmi C, Khar A. Regulation of effector cell functions through the ligation of lymphocyte function-associated antigen-1 and intracellular adhesion molecule-1 leads to spontaneous regression of a rat histiocytoma. Scand J Immunol. 1999; 50(4):378-386. (Clone-specific: Blocking, In vivo exacerbation). View Reference
  5. Fox CC, Jewell SD, Whitacre CC. Rat peritoneal mast cells present antigen to a PPD-specific T cell line. Cell Immunol. 1994; 158(1):253-264. (Clone-specific). View Reference
  6. Liu L, Zhang M, Jenkins C, MacPherson GG. Dendritic cell heterogeneity in vivo: two functionally different dendritic cell populations in rat intestinal lymph can be distinguished by CD4 expression. J Immunol. 1998; 161(3):1146-1155. (Clone-specific). View Reference
  7. Machelska H, Mousa SA, Brack A, et al. Opioid control of inflammatory pain regulated by intercellular adhesion molecule-1. J Neurosci. 2002; 22(13):5588-5596. (Biology). View Reference
  8. Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell. 1994; 76(2):301-314. (Biology). View Reference
  9. Tamatani T, Kotani M, Miyasaka M. Characterization of the rat leukocyte integrin, CD11/CD18, by the use of LFA-1 subunit-specific monoclonal antibodies. Eur J Immunol. 1991; 21(3):627-633. (Clone-specific: Inhibition). View Reference
  10. Tamatani T, Miyasaka M. Identification of monoclonal antibodies reactive with the rat homolog of ICAM-1, and evidence for a differential involvement of ICAM-1 in the adherence of resting versus activated lymphocytes to high endothelial cells. Int Immunol. 1990; 2(2):165-171. (Immunogen: Inhibition). View Reference
  11. Turunen JP, Ustinov J, Renkonen R. Adhesion molecules involved in protein kinase A- and C-dependent lymphocyte adherence to microvascular endothelial cells. Scand J Immunol. 1993; 37(3):282-288. (Biology). View Reference
  12. Watanabe T, Arakawa T, Fukuda T, Higuchi K, Kobayashi K. Role of neutrophils in a rat model of gastric ulcer recurrence caused by interleukin-1 beta. Am J Pathol. 1997; 150(3):971-979. (Biology). View Reference
  13. Westermann J, Nagahori Y, Walter S, Heerwagen C, Miyasaka M, Pabst R. B and T lymphocyte subsets enter peripheral lymph nodes and Peyer's patches without preference in vivo: no correlation occurs between their localization in different types of high endothelial venules and the expression of CD44, VLA-4, LFA-1, ICAM-1, CD2 or L-selectin. Eur J Immunol. 1994; 24(10):2312-2316. (Clone-specific). View Reference
  14. Willenborg DO, Staykova MA, Miyasaka M. Short term treatment with soluble neuroantigen and anti-CD11a (LFA-1) protects rats against autoimmune encephalomyelitis: treatment abrogates autoimmune disease but not autoimmunity. J Immunol. 1996; 157(5):1973-1980. (Clone-specific: Blocking). View Reference
  15. Xia WJ, Schneeberger EE, McCarthy K, Kradin RL. Accessory cells of the lung. II. Ia+ pulmonary dendritic cells display cell surface antigen heterogeneity. Am J Respir Cell Mol Biol. 1991; 5(3):276-283. (Clone-specific). View Reference
  16. Yamazaki T, Seko Y, Tamatani T, et al. Expression of intercellular adhesion molecule-1 in rat heart with ischemia/reperfusion and limitation of infarct size by treatment with antibodies against cell adhesion molecules. Am J Pathol. 1993; 143(2):410-418. (Clone-specific: Inhibition). View Reference
View All (16) View Less
745779 Rev. 1

Please refer to Support Documents for Quality Certificates


Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described


Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims.  Comparisons are not made against non-BD technologies, unless otherwise noted.

For Research Use Only. Not for use in diagnostic or therapeutic procedures.